PN 1018
Alternative Names: PN-1018Latest Information Update: 21 Sep 2020
At a glance
- Originator Polyneuron Pharmaceuticals
- Class Glycopeptides
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Motor neuron disease